drugset / Trial / NCT05215405
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL
Summary
The overall goal of this expanded access program is to provide Venetoclax and Navitoclax to patients with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LL) who have exhausted standard treatments.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navitoclax | Small molecule | 25 mg | Oral |
| Subject | Navitoclax | Small molecule | 50 mg | Oral |
| Subject | Venetoclax | Small molecule | 170 mg | Oral |
| Subject | Venetoclax | Small molecule | 250 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |